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Abstract
Low serum magnesium has been associated with kidney function decline in persons with diabetes 
as well as cardiovascular disease in the general population. Since the association of serum 
magnesium with incident kidney disease in the general population is unknown, we assessed this in 
13,226 participants (aged 45 to 65) in the Atherosclerosis Risk in Communities study with 
baseline estimated glomerular filtration rate of at least 60 ml/min/1.73m2 in years 1987–89 and 
followed through 2010. The risks for incident chronic kidney disease (CKD) and end-stage renal 
disease (ESRD) associated with baseline total serum magnesium levels were evaluated using Cox 
regression. There were 1,965 CKD and 208 ESRD events during a median follow-up of 21 years. 
In adjusted analysis, low serum magnesium levels (0.7mmol/L or less) had significant associations 
with incident CKD and ESRD compared with the highest quartile with adjusted hazard ratio of 
1.58 (95% CI: 1.35–1.87) for CKD and 2.39 (95% CI: 1.61–3.56) for ESRD. These associations 
remained significant after excluding users of diuretics and across subgroups stratified by 
hypertension, diabetes, and self-reported race. Thus, in a large sample of middle-aged adults, low 
total serum magnesium was independently associated with incident CKD and ESRD. Further 
studies are needed to determine whether modification of serum magnesium levels might alter 
subsequent incident kidney disease rates.
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Chronic kidney disease (CKD) affects over 10% of U.S. adults1 and is associated with 
excess mortality risk2 and substantial economic cost, including 18% of the Medicare fee-for-
service expenditure in 2011.1 Although some risk factors for CKD have been established, 
including diabetes, hypertension, older age, and family history of CKD,3, 4 the 
identification of additional, novel risk factors for CKD may improve our understanding of 
the pathogenesis of CKD and allow the development of new CKD prevention strategies.
Magnesium deficiency is an emerging public health concern, even in developed countries.5 
Several lines of evidence suggest low serum magnesium may be a risk factor for incident 
kidney disease. Low magnesium has been associated with higher production of 
inflammatory and pro-atherogenic cytokines in endothelial cells,6 a pathway that could 
contribute to kidney function decline. Indeed, low serum magnesium has been associated 
with kidney function decline in CKD patients7 and patients with diabetes8, 9 as well as 
decreased allograft survival in kidney transplant recipients,10 cardiovascular disease in the 
general population,11 and mortality in hemodialysis patients.12 However, lower serum 
magnesium levels are common in persons at high risk of kidney disease, such as those with 
diabetes or who are treated with diuretics for hypertension;13, 14 thus, whether low serum 
magnesium is a cause or consequence of CKD risk factors and/or treatment is unclear. 
Therefore, we investigated the association of total serum magnesium levels with incident 
CKD and ESRD in participants with estimated glomerular filtration rate (eGFR)≥60mL/min/
1.73m2 in the Atherosclerosis Risk in Communities (ARIC) study, a community-based 
cohort, with particular attention to subgroups by diabetes status and diuretic use.
Results
Study population characteristics
Table 1 presents the baseline characteristics of the study population by five serum 
magnesium levels (Quartiles [Q] 1 to 4 with Q1 subdivided into Q1a [0.25–0.7mmol/L] and 
Q1b [0.75mmol/L]. Individuals with lower total serum magnesium levels were more likely 
to be African-American and female. They also tended to have lower education and income 
levels, higher prevalence of diabetes and hypertension, higher levels of triglycerides, and 
lower serum albumin levels. Among individuals with hypertension, those with lower total 
serum magnesium levels tended to have higher thiazide or loop diuretic use.
During a median of 21 years of follow-up, 1,965 incident CKD events and 208 ESRD events 
occurred in 13,226 individuals. The Kaplan-Meier curves for cumulative incidence of CKD 
or ESRD by five levels of serum magnesium are presented in Figures 1 and 2, respectively.
Association between Serum Magnesium and Incident CKD
Incident CKD was two-fold higher in individuals in the lowest serum magnesium category 
(Q1a, ≤0.7mmol/L) than in those in Q4 (≥0.9mmol/L) (13.09 versus 6.23 per 1000 person-
years, Table 2). There was a graded and inverse relationship between serum magnesium 
levels and incident CKD (p trend<0.001). This graded relationship remained significant in 
all multivariable models (p trend<0.001, Table 3), including those adjusting for diabetes and 
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diuretic use. With adjustment for race-center, age, gender, eGFR, diabetes and hypertension 
medication status (Model 2), individuals in the lowest quartile (Q1a or Q1b) of serum 
magnesium levels had over 1.5 times higher risk of developing CKD than those in Q4 (Q1a 
vs. Q4, adjusted hazard ratio [HR] 1.75, 95% confidence interval [CI]: 1.49–2.06; Q1b vs. 
Q4, adjusted HR 1.58, 95% CI: 1.36–1.83). Further adjustment for education levels, 
household income, medical insurance status, prevalent coronary heart disease, dyslipidemia, 
body mass index, smoking status, and serum albumin (Model 3) resulted in slight 
attenuation of the association (Q1a vs. Q4, adjusted HR 1.58, 95% CI: 1.35–1.87; Q1b vs. 
Q4, adjusted HR 1.47, 95% CI: 1.27–1.71; p for trend<0.001).
Significant associations between low serum magnesium and incident CKD were also found 
after excluding users of thiazide or loop diuretics as well as within subgroups stratified by 
prevalent hypertension or diabetes status or self-reported race (p for trend<0.001 for all 
subgroups, Supplementary Table 1). After excluding users of thiazide or loop diuretics, the 
association between low serum magnesium and incident CKD remained significant (Q1a vs 
Q4: adjusted HR 1.57, 95% CI: 1.31–1.89, p-trend< 0.001). Between individuals with and 
without prevalent hypertension, the associations between serum magnesium and incident 
CKD were not significantly different (no prevalent hypertension, Q1a vs Q4: adjusted HR 
1.52, 95% CI: 1.18–1.96; prevalent hypertension, Q1a vs Q4: adjusted HR 1.63, 95% CI: 
1.31–2.04). Between individuals with and without prevalent diabetes, the association 
between serum magnesium and incident CKD was slightly higher in individuals with 
prevalent diabetes (Q1a vs Q4: adjusted HR 2.12, 95% CI: 1.42–3.17) than in those without 
(adjusted HR 1.48, 95% CI: 1.22–1.79, p for interaction 0.05). Between African Americans 
and European Americans, the association between serum magnesium and incident CKD was 
slightly higher in African Americans (Q1a vs. Q4: adjusted HR 1.93, 95% CI: 1.43–2.62) 
than in European Americans (adjusted HR 1.35, 95% CI: 1.09–1.67, p for interaction 0.02), 
although the associations were similar at higher levels of serum magnesium (African 
Americans, Q1b vs. Q4: adjusted HR 1.47, 95% CI: 1.08, 2.01; European Americans, Q1b 
vs. Q4: adjusted HR 1.53, 95% CI: 1.30, 1.82).
Significant associations between low serum magnesium and incident CKD were also found 
in sensitivity analyses (Supplementary Table 1). The associations between serum 
magnesium levels and incident CKD were similar in analyses treating incident diabetes and 
hypertension during the follow-up period as time-varying covariates. In addition, the 
association between serum magnesium and incident CKD was largely unaffected by 
adjustment for serum calcium, phosphorus, and potassium. Serum magnesium had low 
correlations with calcium (r=0.03) and phosphorus (r=0.04), whereas serum magnesium and 
potassium had moderate correlation (r=0.23). The association between serum magnesium 
and incident CKD defined solely using visit-based eGFR captured over the first 9-years of 
follow-up was similar to the association using the composite definition. Lastly, using the 3-
year visit (visit 2) as the baseline and including adjustment for hemoglobin A1c (HbA1c), 
parathyroid hormone, and high-sensitivity C-reactive protein (hsCRP) levels resulted in 
similar association between serum magnesium and incident CKD. In this latter analysis, 
individuals in Q1a (serum magnesium levels≤0.7mmol/L) were approximately 1.5 times 
more likely to develop CKD than those in Q4 (adjusted HR 1.56, 95% CI: 1.28–1.89).
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Association between serum Magnesium and Incident ESRD
Incident ESRD was six times higher in individuals in the lowest serum magnesium category 
(Q1a, ≤0.7mmol/L) than those in Q3 and Q4 combined (≥0.85mmol/L) (2.62 versus 0.44 per 
1000 person-years, Table 2). Q3 and Q4 of serum magnesium levels were combined as the 
reference group in this analysis to ensure adequate number of individuals in each subgroup 
in multivariate analysis (see Methods section for details). The graded and inverse 
relationship between serum magnesium levels and incident ESRD was significant in all 
multivariate models (p trend<0.001, Table 4). With the adjustment of race-center, age, 
gender, eGFR, diabetes, and hypertension medication status (Model 2), individuals in Q1a 
(≤0.7mmol/L) had approximately 2.5 times higher risk of developing ESRD than those in 
Q3 and Q4 combined (adjusted HR 2.66, 95% CI: 1.80–3.93, p for trend<0.001). After 
further adjustment for other risk factors (Model 3), the association between serum 
magnesium and incident ESRD remained similar (Q1a vs. Q3 and Q4, adjusted HR 2.39, 
95% CI: 1.61–3.56, p for trend<0.001).
In subgroup analyses excluding users of thiazide or loop diuretics, or stratified by prevalent 
hypertension or diabetes status or self-reported race, the association between the lowest 
serum magnesium category (Q1a, ≤0.7mmol/L) and ESRD was significant in all subgroups, 
and there were no statistically significant differences between subgroups (p for interaction 
for all >0.15, Supplementary Table 2). Adjustment for diabetes and hypertension status as 
time-varying covariates did not attenuate the associations between lower serum magnesium 
and the risk of ESRD (Q1a vs. Q3&4, adjusted HR 3.18, 95% CI: 2.16–4.68). Similarly, 
including serum calcium, phosphorus, and potassium, and as covariates or controlling for 
HbA1c, parathyroid hormone, and hsCRP levels with the 3-year visit (visit 2) as the baseline 
did not materially alter the association between serum magnesium and incident ESRD.
Discussion
Main Findings
In a community-based cohort of European and African Americans with eGFR ≥60mL/min/
1.73m2, low serum magnesium levels were associated with incident CKD and ESRD after 
controlling for potential socio-economic and clinical confounders of kidney function 
decline. Individuals in the lowest serum magnesium category (Q1a, ≤0.7mmol/L) were 
approximately 1.6 times more likely to develop incident CKD than those in Q4 
(≥0.9mmol/L) and 2.4 times more likely to develop ESRD than those in Q3 and Q4 
combined (≥0.85mmol/L). These associations did not appear to be confounded by prevalent 
diabetes or the use of diuretics for hypertension treatment, nor did they appear mediated by 
incident diabetes or hypertension. Indeed, significant associations between low serum 
magnesium and incident CKD or ESRD existed across all subgroups stratified by prevalent 
diabetes and hypertension status, and self-reported race.
In the Context of the Literature
To our knowledge, this is the first study to show a prospective association of low serum 
magnesium with incident CKD and ESRD in a community-based cohort with eGFR 
≥60mL/min/1.73m2. Several clinical-based studies have shown associations between low 
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serum magnesium levels and poor kidney outcomes. In patients with type 2 diabetes, low 
serum magnesium levels were associated with kidney function decline or ESRD.8, 9 In 
critically ill patients with acute kidney injury, serum magnesium levels <0.7mmol/L were 
associated with non-recovery of kidney function.15 In kidney transplant recipients with 
chronic cyclosporine nephrotoxicity, serum magnesium levels <0.82mmol/L were associated 
with decreased graft survival.10 The present study expands upon prior work by investigating 
the association between serum magnesium and kidney function in a population-based 
cohort, identifying significant association overall and in individuals with and without 
prevalent diabetes or hypertension.
Although this study is observational and thus cannot provide evidence of a causal 
relationship between magnesium and adverse kidney outcomes, the mechanism underlying 
the association merits further investigation. Previous studies suggest serum magnesium may 
influence kidney function through the regulation of vascular and endothelial function.16 The 
rate of circulating magnesium transport into a cell varies depending on tissue and cell 
type.17 The endothelial cell, which expresses the magnesium transporter TRPM7,18 may be 
more readily influenced by circulating magnesium. In vitro studies have shown that low 
extracellular magnesium levels inhibit endothelial cell proliferation19 and promote the 
expression of inflammatory biomarkers.6 Low magnesium levels have also been shown to 
promote vascular calcification in both in vitro20–23 and in vivo studies.20 Further, serum 
magnesium levels may affect the endothelium through a thrombotic process, since low 
circulating magnesium levels increase platelet aggregation24–26 and have a pro-thrombotic 
effect in animal studies.27, 28 Chronic inflammation and hemostatic biomarkers have been 
linked to kidney function decline.29–33
If circulating magnesium has a causal role in the regulation of vascular and endothelial 
functions, which, in turn, have been implicated in the development of chronic diseases, then 
low circulating magnesium levels could potentially contribute to disease in multiple organs 
in a parallel manner. Endothelial dysfunction has been linked to insulin resistance,34, 35 and 
vascular calcification has been recognized as a risk factor for coronary heart disease.36 Low 
serum magnesium is an independent risk factor of diabetes,37 hypertension,38 and 
cardiovascular disease.11 The potential regulatory role of serum magnesium on vascular and 
endothelial functions may partly explain these independent prospective associations between 
serum magnesium and multiple chronic diseases. On the other hand, serum magnesium 
levels are determined by a constellation of factors, including dietary intake and medications, 
and are regulated by multiple organs. Therefore, low total serum magnesium levels might be 
a marker of disturbances in metabolism or dysregulation of other solutes, which may lead to 
nephrotoxicity in independent ways.39
Strengths and Limitations
Some limitations of our study warrant mention. This study is observational and thus cannot 
provide experimental mechanistic insight on the association between magnesium and 
adverse kidney outcomes. The main analysis was based on a one-time measure of serum 
magnesium with a measurement precision limited to 0.05 mmol/L. Measures of albuminuria 
were not available for adjustment or defining CKD. Biomarkers of chronic inflammation or 
Tin et al. Page 5













endothelial dysfunction were not available to evaluate the hypothesized pathway by which 
serum magnesium might confer renal risk. We cannot exclude the possibility of residual 
confounding from diuretic use and diabetes, although relevant variables were controlled for 
in the analysis. The strengths of our study include a large sample size with a follow-up 
period of over 20 years without weakening of the magnesium association, rigorous 
measurement of many potential confounding variables, and extensive subgroup and 
sensitivity analyses for evaluating potential confounding and mediating effects.
In summary, we have identified low serum magnesium as an independent risk factor for 
incident CKD and ESRD in a large cohort of middle aged adults with eGFR ≥60mL/min/
1.73m2. Associations were robust to multiple sensitivity analyses. Further research is 
required to determine if low total serum magnesium is itself nephrotoxic. If so, our findings 
suggest that magnesium levels may be a novel therapeutic target for the prevention of CKD.
Methods
Study Population
The ARIC Study is a community-based prospective observational study of 15,792 
individuals between the ages of 45 and 64 years. Participants were drawn from a probability-
based sample from 4 US communities (Forsyth County, NC; Jackson, MS; suburban 
Minneapolis, MN; and Washington County, MD). Participants took part in examinations 
starting with the baseline visit (visit 1) between 1987 and 1989. Details of the ARIC cohort 
have been published elsewhere.40
The analyzed sample of 13,226 individuals included participants with baseline eGFR ≥60 
mL/min/1.73m2, fasting time ≥8 hours for blood drawn, and with data in all covariates for 
multivariate analysis. Details on the numbers of individuals not included in analysis are 
reported in Supplementary Table 3.
Incident CKD and ESRD Assessment
Incident CKD was defined using a validated definition as a composite outcome of: 1) a drop 
in eGFR to a level <60 mL/min/1.73m2 at the 3- or 9-year follow-up visits (visits 2 and 4) 
with a concomitant 25% decline in eGFR from baseline (based on the Kidney Disease: 
Improving Global Outcome definition for CKD progression41), 2) a hospitalization or death 
with a diagnostic code indicating CKD (based on the observation that incident CKD was 
strongly associated with non-attendance at subsequent study visits42), or 3) incident ESRD. 
Incident ESRD was identified through linkage with the U.S. Renal Data System (USRDS), a 
national ESRD registry that obtains information on all new ESRD patients through the 
nephrologist-completed Centers for Medicare & Medicaid Services Medical Evidence 
Report. In the ARIC study, active surveillance for hospitalizations and death is performed 
for all participants, and 26 International Classification of Disease, Ninth Revision, Clinical 
Modification (ICD-9-CM) discharge diagnostic codes are abstracted (ICD-10-CM codes in 
the case of deaths).40 The ICD-9-CM and ICD-10-CM codes used for classifying CKD-
related events are reported in Supplementary Table 4. The sensitivity of discharge diagnostic 
code is low (35.5%), but the specificity is high at 95.7%, indicating few false positives.42 
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Most incident CKD events in the present study were captured using hospitalization 
diagnostic codes after the 9-year visit. Of the 1965 incident CKD events reported in the 
present study, 1200 events (61%) were captured solely by the diagnostic codes. Of these 
1200 incident CKD events, 1095 events (91%) occurred after the 9-year visit. The median 
follow-up time of these 1200 incident CKD events was 17 years (interquartile range: 7.2 
years). Participants who died without an event, were lost to follow-up, or survived to the end 
of 2010 without an event were censored.
Measure of Serum Magnesium and Other Variables
Total serum magnesium was measured using the metallochromic dye, Calmagite, based on 
the procedure of Gindler and Heth.43 The measurement precision was 0.05mmol/L. The 
coefficient of variation based on split specimens sent one week apart to the laboratory was 
3%. The short term (<30 days) intra-individual variability as a proportion of the total 
variance of serum magnesium was 0.13.44 The intra-class correlation of serum magnesium 
between the baseline and 3-year visits was 0.45.
Prevalent diabetes mellitus was defined as fasting glucose level at least 126 mg/dL, 
nonfasting glucose level at least 200 mg/dL, or having a self-reported diagnosis of or 
treatment for diabetes. Blood pressure measures were calculated from the last 2 measures of 
three seated blood pressure measures performed by certified technicians using a random-
zero sphygmomanometer after the participant experienced 5 minutes of rest. Self-reported 
antihypertensive medication use was verified by the inspection of medication bottles. 
Hypertension was defined as systolic blood pressure>140mmHg or diastolic blood 
pressure>90mmHg or having a self-reported diagnosis of or treatment for hypertension. 
Hypertension medication status was coded as a four-category variable: no prevalent 
hypertension, hypertension with no medication, hypertension treated with thiazide or loop 
diuretics, and hypertension treated with other medications.
Prevalent coronary heart disease was defined as having a self-reported physician diagnosis 
or a myocardial infarction revealed on the electrocardiogram conducted during the baseline 
visit. Total plasma cholesterol and triglyceride levels were measured using enzymatic 
methods. Low-density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald 
equation45 (excluding those with incalculable LDL because of triglyceride values >400 mg/
dL). Smoking status was based on self-reported. Serum creatinine based eGFR was 
calculated using the equation developed by the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI)46 after standardizing the serum creatinine measures obtained from 
modified kinetic Jaffe assay.47
Statistical Analysis
Serum magnesium levels were categorized into quartiles. Given that 52% of the incident 
ESRD cases were in Q1, we further divided Q1 into sub-quartiles Q1a (≤0.7 mmol/L) and 
Q1b (=0.75mmol/L). Baseline characteristics were compared by the five categories of serum 
magnesium levels using t-tests for non-skewed continuous variables, Wilcoxon tests for 
skewed continuous variable, and Chi-square tests for categorical variables. Kaplan-Meier 
estimates were plotted by serum magnesium categories. Cox proportional hazards regression 
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was used to estimate hazard ratios and 95% confidence intervals for incident CKD or ESRD 
by the five categories of serum magnesium levels. P-values for trend were obtained by 
coding the five categories of serum magnesium as an ordinal variable with values from 0 to 
4. Proportional hazard analyses were performed using SAS 9.3. All other analyses were 
conducted using R.
Using Q4 as the reference group, we estimated the risk for incident CKD associated with 
lower serum magnesium levels in three proportional hazard regression models. The 
covariates were selected a priori based on literature review41, 48–51 and their availability in 
the ARIC study. Model 1 controlled for self-reported race, age, sex, and center. Model 2 
added baseline eGFR, diabetes status, and hypertension medication status, well established 
risk factors of kidney function decline.41 Model 3 added other baseline covariates: education 
levels, household income, health insurance status, systolic blood pressure, prevalent 
coronary heart disease, smoking status, log-transformed triglycerides, high-density 
lipoprotein cholesterol level (HDL-C), log-transformed low density lipoprotein cholesterol 
level (LDL-C), and serum albumin. Although household income was missing in 5% of the 
population, dropping this variable from model 3 so that the study population included 
participants with missing household income led to no meaningful difference in results for 
either incident CKD or incident ESRD. We also considered novel risk factors of CKD that 
are available in the ARIC study, such as leukocyte count, hemostatic factors, and markers of 
heart rate variability.33, 52, 53 Including these variables as covariates had no meaningful 
effect on observed associations (data not shown).
Sensitivity analyses within subgroups were performed to evaluate whether the association 
between serum magnesium and incident CKD might differ by diuretic use, prevalent 
diabetes or hypertension status, or self-reported race. In addition, low serum magnesium 
levels have been shown to be associated with incident diabetes37 or hypertension.38 To 
evaluate potential mediating effects from these two factors, we repeated the analysis for 
Model 3 using incident diabetes and hypertension status as time-varying covariates. Incident 
diabetes and hypertension status were obtained from annual phone interviews up to 2010. 
We also examined whether serum calcium, phosphorus, or potassium might partly account 
for the association between serum magnesium and incident CKD. We calculated the 
Spearman correlation between serum magnesium and these three serum minerals and 
repeated the analysis for Model 3 after adding these serum minerals as covariates. To further 
consider potential confounding, three additional variables were available at the 3-year visit 
(visit 2): parathyroid hormone, hemoglobin A1c (HbA1c), a measure of glycemic control, 
and hsCRP, an acute inflammation biomarker shown to be associated with rapid kidney 
function decline.30 Therefore, we performed the analysis for Model 3 using the 3-year visit 
as the baseline and adding parathyroid hormone, HbA1c, and hsCRP as covariates. We 
evaluated the association between magnesium and incident CKD defined using only visit-
based eGFR as a drop in eGFR to a level <60 mL/min/1.73m2 at the 3- or 9-year follow-up 
visits with a concomitant 25% decline in eGFR. A similar analysis defining incident CKD as 
a drop in eGFR to <60 ml/min/1.73 m2 led to no meaningful difference in results (data not 
shown). Finally, because the proportion of persons with eGFR ≥120 ml/min/1.73 m2 was 
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slightly higher in the low magnesium group, we repeated analyses excluding those with 
eGFR ≥120 ml/min/1.73 m2, again with no difference in results (data not shown).
For incident ESRD, only four individuals had ESRD events in Q4 (≥0.9mmol/L) in African- 
Americans. To ensure each category of serum magnesium had adequate number of events in 
multivariate analyses, we combined Q3 and Q4 as the reference group for incident ESRD 
analyses. Otherwise, the analyses for incident ESRD followed the same steps as outlined 
above for incident CKD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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